1. Home
  2. SWTX vs HGV Comparison

SWTX vs HGV Comparison

Compare SWTX & HGV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SWTX
  • HGV
  • Stock Information
  • Founded
  • SWTX 2017
  • HGV 1992
  • Country
  • SWTX United States
  • HGV United States
  • Employees
  • SWTX N/A
  • HGV N/A
  • Industry
  • SWTX Biotechnology: Pharmaceutical Preparations
  • HGV Hotels/Resorts
  • Sector
  • SWTX Health Care
  • HGV Consumer Discretionary
  • Exchange
  • SWTX Nasdaq
  • HGV Nasdaq
  • Market Cap
  • SWTX 3.5B
  • HGV 3.4B
  • IPO Year
  • SWTX 2019
  • HGV N/A
  • Fundamental
  • Price
  • SWTX $46.26
  • HGV $38.94
  • Analyst Decision
  • SWTX Buy
  • HGV Buy
  • Analyst Count
  • SWTX 7
  • HGV 9
  • Target Price
  • SWTX $56.86
  • HGV $46.44
  • AVG Volume (30 Days)
  • SWTX 8.7M
  • HGV 1.1M
  • Earning Date
  • SWTX 05-20-2025
  • HGV 05-01-2025
  • Dividend Yield
  • SWTX N/A
  • HGV N/A
  • EPS Growth
  • SWTX N/A
  • HGV N/A
  • EPS
  • SWTX N/A
  • HGV 0.34
  • Revenue
  • SWTX $191,589,000.00
  • HGV $4,446,000,000.00
  • Revenue This Year
  • SWTX $86.36
  • HGV $22.28
  • Revenue Next Year
  • SWTX $69.02
  • HGV $4.52
  • P/E Ratio
  • SWTX N/A
  • HGV $114.75
  • Revenue Growth
  • SWTX 3417.33
  • HGV 17.40
  • 52 Week Low
  • SWTX $28.21
  • HGV $30.59
  • 52 Week High
  • SWTX $62.00
  • HGV $45.00
  • Technical
  • Relative Strength Index (RSI)
  • SWTX 58.93
  • HGV 62.14
  • Support Level
  • SWTX $46.10
  • HGV $37.40
  • Resistance Level
  • SWTX $46.27
  • HGV $39.66
  • Average True Range (ATR)
  • SWTX 0.90
  • HGV 1.34
  • MACD
  • SWTX 0.58
  • HGV 0.68
  • Stochastic Oscillator
  • SWTX 99.46
  • HGV 90.24

About SWTX SpringWorks Therapeutics Inc.

SpringWorks Therapeutics Inc is a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing, and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. The company has a differentiated portfolio of small molecule targeted oncology product candidates and is advancing two potentially registrational clinical trials in rare tumor types, as well as several other programs addressing prevalent, genetically defined cancers. OGSIVEO, the first commercial product, is a novel, oral, selective gamma-secretase inhibitor. GOMEKLI, the second commercial product, is an oral, small molecule mitogen-activated protein kinase, or MEK, inhibitor.

About HGV Hilton Grand Vacations Inc.

Hilton Grand Vacations Inc is a timeshare company engaged in developing, marketing, selling, managing, and operating timeshare resorts, timeshare plans, and ancillary reservation services, under the Hilton Grand Vacations brand. The company operates business in the following two segments: (i) Real estate sales and financing and (ii) Resort operations and club management. The majority of the company's revenue is earned through the Real estate sales and financing segment, which generates revenue from VOI sales, and Financing.

Share on Social Networks: